Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter.

Malignant melanoma is characterized by growing incidence, early metastasis, and a lack of effective treatment for advanced disease, suggesting a pressing need for novel therapeutic approaches. Conditionally replicative adenoviruses (CRAds) constitute a new and promising strategy for cancer treatment that has been rapidly translated into clinical trials. We engineered novel melanoma-targeted CRAds, AdTyrdelta24 and AdTyrdelta2delta24, by replacing the adenoviral E1A promoter with a cassette containing a polyA sequence and a human tyrosinase enhancer/promoter construct (hTyr2E/P). The small size of this cassette allows retention of the E3 region within these CRAds, which was shown to enhance viral spread and oncolysis. In addition, we introduced mutations (delta24 and delta2delta24) into the viral E1A gene, which attenuate adenoviral replication in quiescent cells. The cell cycle pathways mediating this attenuation are defective in melanoma cells. By analysis of E1A expression, we prove fidelity of hTyr2E/P in the adenoviral genome and in the context of viral replication when an upstream polyA was included. We further show efficient cytotoxicity of AdTyrdelta24 and AdTyrdelta2delta24 in melanoma cell lines and a 100-1000-fold attenuation in cell lines derived from various nonmelanocytic tissues. Virus replication and progeny production of these viruses were similarly selective, resulting in 200-800-fold higher virus yields in melanoma cells versus control cells, thus establishing viral cytolysis and spread as the cause of the observed cell killing. Cytotoxicity of AdTyrdelta24 for normal fibroblasts and keratinocytes was strongly attenuated, and this virus caused selective killing of melanoma cells but not surrounding keratinocytes in a coculture system. Progeny production and cytotoxicity of AdTyrdelta24 in melanoma cells were similar to matching viruses containing the stronger cytomegalovirus enhancer/promoter instead of hTyr2E/P. Furthermore, AdTyrdelta24 showed a cytopathic effect similar to the wild-type E1A containing AdTyrwt and only minimally reduced compared with wild-type adenovirus. We conclude that the generated CRAds AdTyrdelta24 and AdTyrdelta2delta24 constitute novel targeted agents for gene therapy and viral oncolysis of metastatic melanoma.

[1]  W. Shingleton.  Cutaneous Melanoma: Clinical Management and Treatment Results Worldwide , 1985 .

[2]  Cutaneous Melanoma: Clinical Management and Treatment Results Worldwide , 1985 .

[3]  E. Harlow,et al.  Cellular targets for transformation by the adenovirus E1A proteins , 1989, Cell.

[4]  M. Hitt,et al.  Adenovirus E1A under the control of heterologous promoters: wide variation in E1A expression levels has little effect on virus replication. , 1990, Virology.

[5]  K. Pittman,et al.  Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction , 1991, The Lancet.

[6]  The current management of cutaneous melanoma. , 1991, Advances in surgery.

[7]  P. Hearing,et al.  Redundant elements in the adenovirus type 5 inverted terminal repeat promote bidirectional transcription in vitro and are important for virus growth in vivo. , 1991, Virology.

[8]  Platts-Mills Tae,et al.  Melanogenesis: a Realistic Target for Antimelanoma Therapy? , 1991 .

[9]  R. Vile,et al.  In vitro and in vivo targeting of gene expression to melanoma cells. , 1993, Cancer research.

[10]  J. Pines,et al.  Cyclins and cyclin-dependent kinases: take your partners , 1993 .

[11]  R. Vile,et al.  Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. , 1993, Cancer research.

[12]  P. Kleihues,et al.  Absence of p53 gene mutations in cutaneous melanoma. , 1994, The Journal of investigative dermatology.

[13]  B. Nelson,et al.  Current therapy for cutaneous melanoma. , 1999, Journal of the American Academy of Dermatology.

[14]  H. Hurst,et al.  Suicide gene expression induced in tumour cells transduced with recombinant adenoviral, retroviral and plasmid vectors containing the ERBB2 promoter. , 1996, Gene therapy.

[15]  A. Fattaey,et al.  An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells , 1996, Science.

[16]  R. Fenton,et al.  Transcriptional targeting of recombinant adenoviruses to human and murine melanoma cells. , 1996, Cancer research.

[17]  R. Worton,et al.  Modulation of the specificity and activity of a cellular promoter in an adenoviral vector. , 1997, Human gene therapy.

[18]  J. Simons,et al.  Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. , 1997, Cancer research.

[19]  R. Dummer,et al.  The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. , 1998, Human gene therapy.

[20]  K. Kinzler,et al.  A simplified system for generating recombinant adenoviruses. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[21]  D. Nettelbeck,et al.  A strategy for enhancing the transcriptional activity of weak cell type-specific promoters , 1998, Gene Therapy.

[22]  J. H. Kim,et al.  A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. , 1998, Human gene therapy.

[23]  N. Lemoine,et al.  Insulation of a conditionally expressed transgene in an adenoviral vector , 1999, Gene Therapy.

[24]  O. Wildner,et al.  Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. , 1999, Cancer research.

[25]  Y. Chiang,et al.  A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. , 1999, Human gene therapy.

[26]  Y. Chen,et al.  The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. , 1999, Cancer research.

[27]  D. Nettelbeck,et al.  A dual specificity promoter system combining cell cycle-regulated and tissue-specific transcriptional control , 1999, Gene Therapy.

[28]  Wei-Wei Zhang.  Development and application of adenoviral vectors for gene therapy of cancer , 1999, Cancer Gene Therapy.

[29]  D. Curiel,et al.  Gene therapy for cancer. , 1999, European journal of cancer.

[30]  D. Yu,et al.  Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. , 1999, Cancer research.

[31]  O. Wildner,et al.  Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer , 1999, Gene Therapy.

[32]  W. Wold,et al.  Tumor-Specific, Replication-Competent Adenovirus Vectors Overexpressing the Adenovirus Death Protein , 2000, Journal of Virology.

[33]  A. Lieber,et al.  Insulation from viral transcriptional regulatory elements improves inducible transgene expression from adenovirus vectors in vitro and in vivo , 2000, Gene Therapy.

[34]  M. Piepkorn,et al.  Melanoma genetics: an update with focus on the CDKN2A(p16)/ARF tumor suppressors. , 2000, Journal of the American Academy of Dermatology.

[35]  G. Demers,et al.  Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[36]  V. Krasnykh,et al.  Genetic targeting of adenoviral vectors. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[37]  L. Johnson,et al.  An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy , 2000, Nature Medicine.

[38]  D. Curiel.  The development of conditionally replicative adenoviruses for cancer therapy. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  C. Balagué,et al.  Replicative adenoviruses for cancer therapy , 2000, Nature Biotechnology.

[40]  D. Nettelbeck,et al.  Gene therapy: designer promoters for tumour targeting. , 2000, Trends in genetics : TIG.

[41]  T. McDonnell,et al.  A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo , 2000, Oncogene.

[42]  D. Curiel,et al.  A midkine promoter-based conditionally replicative adenovirus for treatment of pediatric solid tumors and bone marrow tumor purging. , 2001, Cancer research.

[43]  C. Balagué,et al.  Human Papillomavirus E6E7-Mediated Adenovirus Cell Killing: Selectivity of Mutant Adenovirus Replication in Organotypic Cultures of Human Keratinocytes , 2001, Journal of Virology.

[44]  G. Demers,et al.  Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy , 2001, Nature Biotechnology.

[45]  M. Lanuti,et al.  Inclusion of the herpes simplex thymidine kinase gene in a replicating adenovirus does not augment antitumor efficacy , 2001, Gene Therapy.

[46]  R. Kontermann,et al.  Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105). , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[47]  D. Curiel,et al.  Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo , 2001, Nature Biotechnology.

[48]  V. Cerundolo,et al.  Immunotherapy of melanoma , 2001, Immunology.

[49]  Hong Zhang,et al.  A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. , 2001, Cancer research.

[50]  R. Martuza,et al.  Replication-selective virotherapy for cancer: Biological principles, risk management and future directions , 2001, Nature Medicine.

[51]  M. Hitt,et al.  Superior tissue-specific expression from tyrosinase and prostate-specific antigen promoters/enhancers in helper-dependent compared with first-generation adenoviral vectors. , 2002, Human gene therapy.